[0008] In one aspect of the present disclosure, there is provided a pharmaceutical composition comprising a cannabinoid component and a terpene component, the composition comprising:

(a) a cannabinoid component comprising Δ^9-tetrahydrocannabinol (THC) and cannabidiol (CBD) wherein the cannabinoid component comprises:

i) ≥ 40% w/w Δ^9-tetrahydrocannabinol (THC),

ii) ≤ 50% w/w cannabidiol (CBD),

iii) ≥ 0.15 % w/w Cannabigerol (CBG),

iv) ≤ 0.5 % w/w Cannabinodiol (CBN); and

(b) a terpene component comprising:

i) β-caryophyllene in an amount of ≥ 0.4% w/w of the composition,

ii) d-limonene in an amount of ≥ 0.2 % w/w of the composition, and

iii) β-pinene in an amount of ≥ 0.15% w/w of the composition.

[0008a] In another aspect, there is provided the use of a composition as defined above in the manufacture of a medicament for treating chronic pain in a subject.

[0008b] In another aspect, there is provided a pharmaceutical composition as defined above for use in treating chronic pain in a subject.

[0009] In an example, there is provided a method of treating chronic pain, comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition of the disclosure.

[0010] In still a further example, there is provided use of of one or more of a pharmaceutical composition of the disclosure in the manufacture of a medicament for treating chronic pain.

[0011] In yet another example of the disclosure, there is provided a pharmaceutical composition of the disclosure for use in treating chronic pain.

Definitions

[0012] The term “cannabinoid” as used herein relates to any compound that has been isolated from a *Cannabis* plant or synthetically created that has activity involving the endocannabinoid system. The term is used to describe the relevant compound itself irrespective of its source.

[0013] The term “cannabinoid combination” is used to describe the combination of cannabinoid compounds obtained from one or more Cannabis extracts or combinations of

Claims

1. A pharmaceutical composition comprising a cannabinoid component and a terpene component, the composition comprising:

   (a) a cannabinoid component comprising Δ^9-tetrahydrocannabinol (THC), cannabidiol (CBD) wherein the cannabinoid component comprises:

   i) ≥ 40% w/w Δ^9-tetrahydrocannabinol (THC),

   ii) ≤ 50% w/w cannabidiol (CBD),

   iii) ≥ 0.15 % w/w Cannabigerol (CBG),

   iv) ≤ 0.5 % w/w Cannabinodiol (CBN); and

   (b) a terpene component comprising:

   i) β-caryophyllene in an amount of ≥ 0.4% w/w of the composition,

   ii) d-limonene in an amount of ≥ 0.2 % w/w of the composition, and

   iii) β-pinene in an amount of ≥ 0.15% w/w of the composition.

2. The pharmaceutical composition according to claim 1 wherein the ratio of THC:CBD is about 2:1 to about 1:1.

3. The pharmaceutical composition according to claim 2 wherein the ratio of THC:CBD/CBG is about 1:1.

4. The pharmaceutical composition according to any one of claims 1 to 3 wherein the cannabinoid component is present in an amount of about 1% to about 10% w/w of the composition.

5. The pharmaceutical composition according to claim 4 wherein the cannabinoid component is present in an amount of about 2.5 to about 3.5 % w/w of the composition.

6. The pharmaceutical composition according to any one of claims 1 to 5 wherein the terpene component is present in an amount of about 0.75 % w/w to about 10% w/w of the composition.

7. The pharmaceutical composition according to claim 6 wherein the terpene

component is present in an amount of about 0.75% w/w to about 1.25 % w/w of the composition.

8. The pharmaceutical composition according to any one of claims 1 to 7 wherein the β-caryophyllene is present in an amount of about 0.4% w/w to about 5% w/w of the composition

9. The pharmaceutical composition according to claim 8 wherein the β-caryophyllene is present in an amount of about 0.4% w/w to about 0.5% w/w of the composition.

10. The pharmaceutical composition according to any one of claims 1 to 9 wherein the d-limonene is present in an amount of about 0.2% w/w to about 5% w/w of the composition.

11. The pharmaceutical composition according to claim 10 wherein the d-limonene is present in an amount of about 0.2% w/w to about 0.3% w/w of the composition.

12. The pharmaceutical composition according to any one of claims 1 to 11 wherein the β-pinene is present in an amount of about 0.15% w/w to about 5% w/w of the composition.

13. The pharmaceutical composition according to claim 12 wherein the β-pinene is present in an amount of about 0.15% w/w to about 0.25% w/w of the composition.

14. Use of a composition of any one of claims 1 to 13 in the manufacture of a medicament for treating chronic pain in a subject.

15. A pharmaceutical composition according to any one of claims 1 to 13 for use in treating chronic pain in a subject.

16. The use according to claim 14 or the composition according to claim 15 wherein the subject is an athlete or retired athlete.

17. The use or composition according to any one of claims 14 to 16 wherein the chronic pain is a result of injury sustained during training or sport.

18. The use or composition according to any one of claims 14 to 16 wherein the chronic pain is a result of over use or repetitive action that develops over time.

19. The use or composition according to any one of claims 14 to 16 wherein the chronic pain is arthritic pain, back pain, joint pain, inflammatory pain or nerve pain.